Showing 1,721 - 1,740 results of 101,561 for search '(( end point decrease ) OR ( 5 ((((mean decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 0.96s Refine Results
  1. 1721
  2. 1722
  3. 1723
  4. 1724
  5. 1725
  6. 1726
  7. 1727
  8. 1728
  9. 1729

    Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl, a decrease of downstream phosphorylated STAT5 and a caspase-dependent cell death in TKIs-resistant and –sensitive K562 cell lines. by Octavian Bucur (470431)

    Published 2013
    “…K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed by the detection of Bcr-Abl and phosphorylated STAT5. The combined treatment resulted in a marked decrease of the total levels of Bcr-Abl, which correlates with a decrease in the phosphorylation of the downstream STAT5 protein, in both K562 and K562-R cells. β-Actin was used as an internal loading control. …”
  10. 1730
  11. 1731
  12. 1732
  13. 1733
  14. 1734

    Image2_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  15. 1735

    Image1_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  16. 1736
  17. 1737
  18. 1738
  19. 1739
  20. 1740